Do analysts prefer ADIL or RYM?

Adial Pharmaceuticals presently has a consensus target price of $8.33, indicating a potential upside of 153.29%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Adial Pharmaceuticals is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ADIL or VERU more profitable?

Veru's return on equity of -47.58% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -203.87% -512.41% Veru N/A -47.58% -35.83%

Is ADIL or SCYX more profitable?

SCYNEXIS's return on equity of -44.15% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -203.87% -512.41% SCYNEXIS N/A -44.15% -32.61%

Which has better earnings and valuation, FLNA or ADIL?

Cassava Sciences is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$0.87 N/A Adial Pharmaceuticals N/A N/A -$7.98M -$14.73 N/A

Is FLNA or ADIL more profitable?

Cassava Sciences' return on equity of -58.78% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -58.78% -36.74% Adial Pharmaceuticals N/A -203.87% -512.41%

Is ADIL or IXHL more profitable?

Incannex Healthcare's return on equity of -25.62% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -203.87% -512.41% Incannex Healthcare N/A -25.62% -24.46%

Adial Pharmaceuticals (ADIL) Competitors

$3.20 -0.10 (-2.89%)

As of 01:24 PM Eastern

Compare

ADIL vs. RYM, VERU, SCYX, FLNA, and IXHL

Should you buy Adial Pharmaceuticals stock or one of its competitors? Adial Pharmaceuticals's main competitors and comparable companies include RYTHM (RYM), Veru (VERU), SCYNEXIS (SCYX), Cassava Sciences (FLNA), and Incannex Healthcare (IXHL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Adial Pharmaceuticals compare to RYTHM?

Adial Pharmaceuticals (NASDAQ:ADIL) and RYTHM (NASDAQ:RYM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Adial Pharmaceuticals presently has a consensus target price of $8.33, indicating a potential upside of 153.29%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Adial Pharmaceuticals is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Adial Pharmaceuticals has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-203.87%	-512.41%
RYTHM	-6.20%	-12.57%	-2.60%

In the previous week, Adial Pharmaceuticals and Adial Pharmaceuticals both had 1 articles in the media. Adial Pharmaceuticals' average media sentiment score of 1.82 beat RYTHM's score of 1.79 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Adial Pharmaceuticals	Very Positive
RYTHM	Very Positive

Adial Pharmaceuticals has higher earnings, but lower revenue than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A
RYTHM	$17.28M	2.40	-$33.26M	-$10.53	N/A

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 6.0% of RYTHM shares are held by institutional investors. 8.0% of Adial Pharmaceuticals shares are held by insiders. Comparatively, 3.5% of RYTHM shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Adial Pharmaceuticals has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, RYTHM has a beta of 9.46, indicating that its share price is 846% more volatile than the broader market.

Summary

Adial Pharmaceuticals beats RYTHM on 8 of the 13 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Veru?

Adial Pharmaceuticals (NASDAQ:ADIL) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

In the previous week, Veru had 1 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 2 mentions for Veru and 1 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 1.82 beat Veru's score of 0.93 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Adial Pharmaceuticals	Very Positive
Veru	Positive

Veru's return on equity of -47.58% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-203.87%	-512.41%
Veru	N/A	-47.58%	-35.83%

Adial Pharmaceuticals presently has a consensus target price of $8.33, indicating a potential upside of 153.29%. Veru has a consensus target price of $24.50, indicating a potential upside of 1,018.72%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Adial Pharmaceuticals has higher earnings, but lower revenue than Veru. Veru is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A
Veru	$16.89M	2.21	-$22.73M	-$0.69	N/A

Adial Pharmaceuticals has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Veru has a beta of -1.21, suggesting that its share price is 221% less volatile than the broader market.

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 8.0% of Adial Pharmaceuticals shares are held by insiders. Comparatively, 14.2% of Veru shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Veru beats Adial Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to SCYNEXIS?

Adial Pharmaceuticals (NASDAQ:ADIL) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Adial Pharmaceuticals presently has a consensus price target of $8.33, suggesting a potential upside of 153.29%. SCYNEXIS has a consensus price target of $33.00, suggesting a potential upside of 727.07%. Given SCYNEXIS's stronger consensus rating and higher possible upside, analysts plainly believe SCYNEXIS is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, SCYNEXIS had 3 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 4 mentions for SCYNEXIS and 1 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 1.82 beat SCYNEXIS's score of 1.02 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Adial Pharmaceuticals	Very Positive
SCYNEXIS	Positive

16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 8.0% of Adial Pharmaceuticals shares are owned by insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

SCYNEXIS's return on equity of -44.15% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-203.87%	-512.41%
SCYNEXIS	N/A	-44.15%	-32.61%

Adial Pharmaceuticals has higher earnings, but lower revenue than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A
SCYNEXIS	$20.60M	1.93	-$8.61M	-$2.09	N/A

Adial Pharmaceuticals has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

Summary

SCYNEXIS beats Adial Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Cassava Sciences has a beta of -0.65, indicating that its stock price is 165% less volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

Cassava Sciences presently has a consensus target price of $5.00, indicating a potential upside of 572.59%. Adial Pharmaceuticals has a consensus target price of $8.33, indicating a potential upside of 153.29%. Given Cassava Sciences' higher probable upside, equities analysts plainly believe Cassava Sciences is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Cassava Sciences is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A

In the previous week, Cassava Sciences had 1 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 2 mentions for Cassava Sciences and 1 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 1.82 beat Cassava Sciences' score of 0.91 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Cassava Sciences	Positive
Adial Pharmaceuticals	Very Positive

Cassava Sciences' return on equity of -58.78% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
Adial Pharmaceuticals	N/A	-203.87%	-512.41%

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 8.0% of Adial Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Cassava Sciences and Adial Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Incannex Healthcare?

Adial Pharmaceuticals (NASDAQ:ADIL) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Adial Pharmaceuticals has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 6.97, suggesting that its share price is 597% more volatile than the broader market.

Adial Pharmaceuticals currently has a consensus price target of $8.33, indicating a potential upside of 153.29%. Incannex Healthcare has a consensus price target of $18.00, indicating a potential upside of 518.56%. Given Incannex Healthcare's higher possible upside, analysts plainly believe Incannex Healthcare is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Incannex Healthcare	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Incannex Healthcare had 3 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 4 mentions for Incannex Healthcare and 1 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 1.82 beat Incannex Healthcare's score of 0.43 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Adial Pharmaceuticals	Very Positive
Incannex Healthcare	Neutral

Adial Pharmaceuticals has higher earnings, but lower revenue than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A
Incannex Healthcare	$90K	405.78	-$19.30M	-$1.69	N/A

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 8.0% of Adial Pharmaceuticals shares are held by insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Incannex Healthcare's return on equity of -25.62% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-203.87%	-512.41%
Incannex Healthcare	N/A	-25.62%	-24.46%

Summary

Incannex Healthcare beats Adial Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Adial Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADIL vs. The Competition

Export

Metric	Adial Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.40M	$12.42B	$7.27B	$12.97B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-0.22	807.81	275.40	25.37
Price / Sales	N/A	748.45	562.29	78.82
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	0.67	9.21	10.55	5.95
Net Income	-$7.98M	$2.84B	$3.50B	$380.75M
7 Day Performance	-19.92%	-4.00%	-3.92%	-3.96%
1 Month Performance	-36.10%	-8.07%	-8.30%	-6.81%
1 Year Performance	-65.77%	-5.86%	2.35%	-4.58%

Adial Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADIL Adial Pharmaceuticals	2.7255 of 5 stars	$3.20 -2.9%	$8.33 +160.8%	-64.4%	$8.40M	N/A	N/A	6	Analyst Downgrade
RYM RYTHM	0.8264 of 5 stars	$19.42 -0.5%	N/A	-58.2%	$42.33M	$17.28M	N/A	141	Positive News Gap Up
VERU Veru	3.2031 of 5 stars	$2.47 +2.2%	$24.50 +890.3%	-47.1%	$42.06M	$16.89M	N/A	230	News Coverage Analyst Forecast Gap Up
SCYX SCYNEXIS	3.0083 of 5 stars	$4.11 -2.7%	$33.00 +703.5%	-38.6%	$40.87M	$20.60M	N/A	29	Positive News
FLNA Cassava Sciences	3.4934 of 5 stars	$0.83 +2.0%	$5.00 +502.3%	-81.9%	$40.10M	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADIL) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adial Pharmaceuticals (ADIL) Competitors

ADIL vs. RYM, VERU, SCYX, FLNA, and IXHL

How does Adial Pharmaceuticals compare to RYTHM?

Summary

How does Adial Pharmaceuticals compare to Veru?

Summary

How does Adial Pharmaceuticals compare to SCYNEXIS?

Summary

How does Adial Pharmaceuticals compare to Cassava Sciences?

Summary

How does Adial Pharmaceuticals compare to Incannex Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL vs. The Competition

Adial Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adial Pharmaceuticals (ADIL) Competitors

ADIL vs. RYM, VERU, SCYX, FLNA, and IXHL

How does Adial Pharmaceuticals compare to RYTHM?

Do analysts prefer ADIL or RYM?

Is ADIL or RYM more profitable?

Does the media favor ADIL or RYM?

Which has higher valuation and earnings, ADIL or RYM?

Do institutionals and insiders believe in ADIL or RYM?

Which has more risk and volatility, ADIL or RYM?

Summary

How does Adial Pharmaceuticals compare to Veru?

Does the media favor ADIL or VERU?

Is ADIL or VERU more profitable?

Do analysts recommend ADIL or VERU?

Which has preferable valuation and earnings, ADIL or VERU?

Which has more volatility and risk, ADIL or VERU?

Do insiders & institutionals believe in ADIL or VERU?

Summary

How does Adial Pharmaceuticals compare to SCYNEXIS?

Do analysts prefer ADIL or SCYX?

Does the media refer more to ADIL or SCYX?

Do insiders and institutionals hold more shares of ADIL or SCYX?

Is ADIL or SCYX more profitable?

Which has higher earnings & valuation, ADIL or SCYX?

Which has more risk & volatility, ADIL or SCYX?

Summary

How does Adial Pharmaceuticals compare to Cassava Sciences?

Which has more volatility & risk, FLNA or ADIL?

Do analysts prefer FLNA or ADIL?

Which has better earnings and valuation, FLNA or ADIL?

Does the media favor FLNA or ADIL?

Is FLNA or ADIL more profitable?

Do institutionals & insiders believe in FLNA or ADIL?

Summary

How does Adial Pharmaceuticals compare to Incannex Healthcare?

Which has more risk & volatility, ADIL or IXHL?

Do analysts prefer ADIL or IXHL?

Does the media prefer ADIL or IXHL?

Which has higher valuation & earnings, ADIL or IXHL?

Do insiders and institutionals believe in ADIL or IXHL?

Is ADIL or IXHL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL vs. The Competition

Adial Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools